Judo Bio
CAMBRIDGE, MA · Biotechnology · 200 employees
Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases. With our STRIKE (Selectively Targeting RNA Into KidnEy) platform, we are using a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated update by specific kidney cell types, resulting in gene silencing of disease-modi
Funding history
- Series seed — $100.0M — Oct 2024
- Funding Round — $20.0M — Nov 2022
Recent signals
- Oct 07, 2024: Judo Bio appoints Rajiv Patni as Chief Executive Officer
- Oct 07, 2024: Raised $100.0M in Series seed
- Nov 22, 2022: Raised $20.0M
See plans & pricing → Track Judo Bio’s funding, hiring, and signals — with verified contacts — on Fundz.